LOGIN  |  REGISTER
Amneal Pharmaceuticals

ThermoGenesis (NASDAQ: THMO) Stock Quote

Last Trade: US$0.0006
Volume: 0
5-Day Change: -99.90%
YTD Change: -99.90%
Market Cap: US$10K

Latest News From ThermoGenesis

Conference Call to be Held Today at 1:30 p.m. PT / 4:30 p.m. ET RANCHO CORDOVA, Calif. , Nov. 13, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported financial and operating results for the third quarter ended September 30, 2023 , and provided a corporate business update. "In October, we were... Read More
Conference Call to be Held on November 13, 2023 RANCHO CORDOVA, Calif. , Nov. 8, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the third quarter ended September 30, 2023 , and provide a corporate strategic update on Thursday, November... Read More
An ISO 7 cGMP Cleanroom Facility Grand Opening On October 26, 2023 RANCHO CORDOVA, Calif. , Oct. 26, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing and cell and gene therapy services, announced the grand opening of its new state-of-the-art facility, housing ISO 7 cGMP cleanroom suites, along with research and development labs. The Grand Opening Celebration for... Read More
RANCHO CORDOVA, Calif. , Sept. 6, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that Chris Xu , Ph.D., Chief Executive Officer, will present a company overview on Wednesday, September 13 , at 4:30 pm ET , during the H.C. Wainwright 25th Annual Global Investment Conference, taking place... Read More
Conference Call to be Held Today at 1:30 p.m. PT / 4:30 p.m. ET RANCHO CORDOVA, Calif. , Aug. 10, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported financial and operating results for the second quarter ended June 30, 2023 , and provided a corporate business update. "Throughout the second... Read More
Conference Call to be Held on August 10, 2023 RANCHO CORDOVA, Calif. , Aug. 8, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the second quarter ended June 30, 2023 , and provide a corporate strategic update on Thursday, August 10, 2023... Read More
RANCHO CORDOVA, Calif. , July 17, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced the appointments of Biao Xi, Ph.D. and James Xu, Esq. , DBA, PsyD., J.D., CPA to its Board, effective July 17, 2023 . Both are independent directors. The appointments expand ThermoGenesis' Board to seven members.... Read More
Conference Call to be Held Today at 1:30 p.m. PT / 4:30 p.m. ET RANCHO CORDOVA, Calif. , May 15, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported financial and operating results for the first quarter ended March 31, 2023 and provided a corporate strategic update. "During the first quarter, we... Read More
Conference Call to be Held on May 15, 2023 RANCHO CORDOVA, Calif. , May 10, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the first quarter ended March 31, 2023 and provide a corporate strategic update on Monday, May 15, 2023 , after... Read More
Conference Call to be Held Today at 1:30 p.m. PT / 4:30 p.m. ET RANCHO CORDOVA, Calif. , March 30, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported financial and operating results for the year ended December 31, 2022 and provided a corporate strategic update. "We are transforming ThermoGenesis... Read More
Conference Call to be Held on March 30, 2023 RANCHO CORDOVA, Calif. , March 28, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that the Company will release its financial results for the year ended December 31, 2022 and provide a corporate strategic update on Thursday, March 30, 2023 , after the... Read More
RANCHO CORDOVA, Calif. , March 20, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced the closing of its previously announced purchase and sale of 1,071,429 shares of its common stock (or common stock equivalents) and warrants to purchase up to 1,071,429 shares of its common stock at a purchase... Read More
RANCHO CORDOVA, Calif. , March 16, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that it has entered into definitive agreements for the purchase and sale of 1,071,429 shares of its common stock (or common stock equivalents) and warrants to purchase 1,071,429 shares of its common stock at a... Read More
RANCHO CORDOVA, Calif. , March 15, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. ( Nasdaq : THMO ), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company is rolling out a new facility in the Sacramento metro area, containing a total of 12, class-7, ReadyStart cGMP Suites available for lease by early-stage life science and cell gene therapy ("... Read More
RANCHO CORDOVA, Calif. , Jan. 11, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ: THMO) (the "Company"), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced it has received notice from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Nasdaq's minimum bid price for continued listing on the Nasdaq Capital Market set... Read More
RANCHO CORDOVA, Calif. , Dec. 21, 2022 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ: THMO) (the "Company"), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced a 1-for-45 reverse stock split of its outstanding common stock, effective at 12:01 a.m. Eastern time on December 22 , 2022. Beginning tomorrow, December 22, 2022 , the Company's common stock will... Read More
Astria Therapeutics

COPYRIGHT ©2023 HEALTH STOCKS HUB